A new once-daily oral GLP-1 drug is adding momentum to the rapidly changing obesity-treatment market. In a Phase 2b trial published in Nature Medicine, the experimental drug aleniglipron produced up to 12.1% average weight loss after 36 weeks in adults with overweight or obesity.
The result is notable not simply because of the amount of weight lost, but because aleniglipron is a small-molecule GLP-1 receptor agonist designed to be taken as a pill rather than delivered as a peptide injection.
Aleniglipron: The New GLP-1 Pill
The randomized, double-blind trial involved 230 adults treated at 38 U.S. medical centers. Participants received 45 mg, 90 mg or 120 mg of aleniglipron once daily, with doses increased every four weeks, or placebo.
At week 36, average body-weight changes were:
- 45 mg: −9.0%
- 90 mg: −10.7%
- 120 mg: −12.1%
- Placebo: −0.8%
The highest dose therefore produced an approximately 12% average reduction in body weight. The placebo-adjusted reduction at 120 mg was 11.3 percentage points.
Why a Small-Molecule GLP-1 Matters
Today’s best-known obesity medicines include injectable semaglutide and tirzepatide. Oral GLP-1 treatments are now changing that landscape.
Aleniglipron is different because it is a non-peptide small molecule. In principle, this type of drug could offer manufacturing and distribution advantages compared with peptide-based therapies and may make large-scale production easier.
Convenience is another potential advantage. The trial evaluated once-daily oral treatment, and the drug is being developed as an obesity therapy rather than simply as an alternative formulation of an existing injection.
The Pill Race Is Already Underway
Aleniglipron is entering a market that has already changed dramatically in 2026.
Foundayo (orforglipron), Eli Lilly’s oral GLP-1 receptor agonist, received U.S. approval in April 2026. It is a small-molecule GLP-1 drug that can be taken once daily without food or water restrictions.
The competition is now extending beyond the United States. On August 10, 2026, the UK’s Medicines and Healthcare products Regulatory Agency approved Foundayo, making the UK the first European country to authorize it.
Meanwhile, injectable drugs remain extremely important. Eli Lilly reported strong 2026 demand for Zepbound and Mounjaro, while Novo Nordisk is also competing with oral semaglutide.
What About Side Effects?
In the aleniglipron Phase 2b trial, gastrointestinal side effects were generally mild to moderate and became less frequent during treatment. Overall, 10.4% of participants discontinued treatment, and researchers reported no cases of drug-induced liver injury.
However, these findings do not establish the long-term safety or effectiveness of the drug. Aleniglipron remains investigational, and Phase 3 testing is the next major step.
A New Era of Weight-Loss Pills?
The significance of aleniglipron may ultimately extend beyond its 12.1% result. The obesity-drug industry is moving toward a broader choice of daily oral treatments, higher-dose formulations and potentially easier-to-manufacture molecules.
For patients who dislike injections, an effective oral GLP-1 could remove an important barrier. But the real test will be whether larger, longer Phase 3 trials confirm the weight-loss results, safety and durability.
Bottom line: Aleniglipron is not yet an approved weight-loss medicine, but its 12.1% average weight reduction at 36 weeks adds another important contender to the rapidly expanding GLP-1 pill race.
Medical disclaimer: This article is for educational purposes only. Aleniglipron is an investigational drug and should not be used outside an appropriate clinical setting. Weight-loss medicines should be discussed with a qualified healthcare professional.
